0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia

Stanley R. Frankel, MD; Anna Eardley, BS; Gregory Lauwers, MD; Mark Weiss, MD; and Raymond P. Warrell Jr., MD
[+] Article and Author Information

This article was presented in part at the 33rd Annual Meeting of the American Society of Hematology, December 1991.

Grant Support: In part by grant FD-R-000674 from the Orphan Product Division, Food and Drug Administration, and grant CA-09207-14 from the National Cancer Institute, Department of Health and Human Services; the Mortimer J. Lacher Research Fund; and the Coleman Leukemia Research Fund. All-trans retinoic acid was kindly supplied by Hoffmann LaRoche Inc., Nutley, New Jersey.

Requests for Reprints: Raymond P. Warrell, Jr., MD, Memorial SloanKettering Cancer Center, 1275 York Avenue, New York, NY 10021.

Current Author Addresses: Drs. Warrell, Lauwers, and Weiss, and Ms. Eardley: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.

Dr. Frankel: Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263.


©1992 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1992;117(4):292-296. doi:10.7326/0003-4819-117-4-292
Text Size: A A A

Objective: To describe a novel complication of therapy with all-trans retinoic acid in patients with acute promyelocytic leukemia. ▪Design: Case series. ▪Setting: Comprehensive cancer center. ▪Patients: Consecutive patients with a morphologic diagnosis of acute promyelocytic leukemia who underwent remission induction treatment with all-trans retinoic acid, 45 mg/m2 body surface area per day. ▪Measurements and Results: Nine of 35 patients (26%; 95% Cl, 9% to 52%) with acute promyelocytic leukemia who were treated with all-trans retinoic acid developed a syndrome consisting primarily of fever and respiratory distress. Additional prominent signs and symptoms included weight gain, lower-extremity edema, pleural or pericardial effusions, and episodic hypotension. The onset of this symptom complex occurred from 2 to 21 days after starting treatment. Three deaths occurred; post-mortem examinations in two patients showed pulmonary interstitial infiltration with maturing myeloid cells. Six other patients survived, each achieving complete remission (five patients with all-trans retinoic acid only; 1 patient with chemotherapy). In six of the nine cases, the onset of the syndrome was preceded by an increase in peripheral blood leukocytes to a level of at least 20 ÷109 cells/L. Certain therapeutic interventions, including leukapheresis, temporary cessation of therapy with all-trans retinoic acid, and cytotoxic chemotherapy in moderate doses were not useful after respiratory distress was established. However, the administration of high-dose corticosteroid therapy (dexamethasone, 10 mg IV intravenously every 12 hours for 3 or more days) early in the course of the syndrome resulted in prompt symptomatic improvement and full recovery in three of four patients. ▪Conclusions: The use of all-trans retinoic acid to induce hematologic remission in patients with acute promyelocytic leukemia is associated in some patients with the development of a potentially lethal syndrome that is not uniformly accompanied by peripheral blood leukocytosis. Early recognition of the symptom complex of fever and dyspnea, combined with prompt corticosteroid treatment, may decrease morbidity and mortality associated with this syndrome.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)